May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
AAV-Mediated Gene Therapy Restores Cone System Functions in cpfl5 Mouse, a Model of Human Achromatopsia With CNGA3 Mutation
J.-J. Pang; B. Lei; W. Deng; Y. Umino; D. Everhart; Q. Li; B. Chang; M. Biel; R. Barlow; W. W. Hauswirth
Author Affiliations & Notes
  • J.-J. Pang
    Ophthalmology, University of Florida, Gainesville, Florida
  • B. Lei
    Veterinary Medicine and Surgery, Ophthalmology, University of Missouri-Columbia, Columbia, Missouri
  • W. Deng
    Ophthalmology, University of Florida, Gainesville, Florida
  • Y. Umino
    Ophthalmology, SUNY Upstate Medical University, Syracuse, New York
  • D. Everhart
    Ophthalmology, SUNY Upstate Medical University, Syracuse, New York
  • Q. Li
    Ophthalmology, University of Florida, Gainesville, Florida
  • B. Chang
    The Jackson Laboratory, Bar Harbor, Maine
  • M. Biel
    Munich Center for Integrated Protein Science and Dept. of Pharmacy, Center for Drug Research, University of Munich, Munich, Germany
  • R. Barlow
    Ophthalmology, SUNY Upstate Medical University, Syracuse, New York
  • W. W. Hauswirth
    Ophthalmology, University of Florida, Gainesville, Florida
  • Footnotes
    Commercial Relationships  J. Pang, None; B. Lei, None; W. Deng, None; Y. Umino, None; D. Everhart, None; Q. Li, None; B. Chang, None; M. Biel, None; R. Barlow, None; W.W. Hauswirth, AGTC, P.
  • Footnotes
    Support  NIH grants, EY13729, EY11123, NS36302, EY08571, EY007758, EY00667, EY018331 and FFB, MVRF, RPB, Lions of Central NY
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5355. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      AAV-Mediated Gene Therapy Restores Cone System Functions in cpfl5 Mouse, a Model of Human Achromatopsia With CNGA3 Mutation
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      J.-J. Pang, B. Lei, W. Deng, Y. Umino, D. Everhart, Q. Li, B. Chang, M. Biel, R. Barlow, W. W. Hauswirth; AAV-Mediated Gene Therapy Restores Cone System Functions in cpfl5 Mouse, a Model of Human Achromatopsia With CNGA3 Mutation. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5355. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose: : Mutations in the gene encoding the alpha-subunit of the cone cyclic nucleotide-gated (CNGA3) channels cause cone function loss in mammals including humans. We tested if AAV-mediated Cnga3 gene therapy can restore cone system function in cpfl5 (Cone Photoreceptor Function Loss 5) mice, a natural model of human Achromatopsia 2 with Cnga3 mutation.

Methods: : At postnatal day 14, 1 µl of AAV5-CBA-Cnga3 vector (1 x 1013 viral particles /ml) was injected subretinally into one eye of 30 cpfl5 mice. The untreated contralateral eye was used as a control. Dark- and light-adapted ERGs were recorded periodically from 3 to 20 weeks after injections. 20 weeks after treatment, visual function was assessed with routine ERGs and dark-adapted flicker ERGs. Visual acuity and contrast sensitivity were also measured 20 weeks after treatment. Then both treated and control eyes were harvested for histochemical studies.

Results: : In treated eyes, restored light-adapted ERG waveforms were recorded 3 weeks after injections and remained stable for at least 20 weeks. The ERG amplitudes were about 60-70% of those of normal C57BL/6J mice. Cone-driven ERGs were not recordable from contralateral untreated eyes. Dark-adapted flicker ERGs indicate that the treatment significantly improved the cone-driven responses but had no effect on rod-driven responses. Behavioral tests showed near normal cone-driven visual acuity and contrast sensitivity in the treated but not in untreated eyes of cpfl5 mice. Immunohistochemistry showed CNGA3 staining in the outer segments of most cones in the treated eyes but not in cones from partner untreated eyes.

Conclusions: : AAV mediated gene therapy corrects a cone CNGA3 deficiency in a naturally occurring mouse model of human Achromatopsia 2. The genetic intervention restores the cone system function as demonstrated by ERG and behavioral tests.

Keywords: color vision • gene transfer/gene therapy • retinal degenerations: hereditary 
© 2008, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2015 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept